ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial
The Lancet Oncology
◽
10.1016/s1470-2045(16)30661-1
◽
2017
◽
Vol 18
(2)
◽
pp. 181-191
◽
Cited By ~ 131
Author(s):
Abdel-Rahmène Azzouzi
◽
Sébastien Vincendeau
◽
Eric Barret
◽
Antony Cicco
◽
François Kleinclauss
◽
...
Keyword(s):
Prostate Cancer
◽
Photodynamic Therapy
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Risk Prostate Cancer
◽
Open Label Phase
◽
Low Risk Prostate Cancer
◽
Randomised Controlled
◽
Targeted Photodynamic Therapy
Download Full-text
Related Documents
Cited By
References
Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial
The Journal of Urology
◽
10.1016/j.juro.2017.05.029
◽
2017
◽
Vol 198
(2)
◽
pp. 255-257
◽
Cited By ~ 1
Author(s):
Samir S. Taneja
Keyword(s):
Prostate Cancer
◽
Photodynamic Therapy
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Risk Prostate Cancer
◽
Open Label Phase
◽
Low Risk Prostate Cancer
◽
Randomised Controlled
◽
Targeted Photodynamic Therapy
Download Full-text
Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial
Urology
◽
10.1016/j.urology.2017.03.020
◽
2017
◽
Vol 104
◽
pp. 7-8
Author(s):
James Johnston
◽
Werner J. Struss
◽
Peter C. Black
Keyword(s):
Prostate Cancer
◽
Randomized Controlled Trial
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Randomized Controlled
◽
Risk Prostate Cancer
◽
Open Label Phase
◽
Low Risk Prostate Cancer
◽
Targeted Photodynamic Therapy
Download Full-text
Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO
SSRN Electronic Journal
◽
10.2139/ssrn.3478102
◽
2019
◽
Author(s):
Chiara Cremolini
◽
Carlotta Antoniotti
◽
Daniele Rossini
◽
Sara Lonardi
◽
Fotios Loupakis
◽
...
Keyword(s):
Colorectal Cancer
◽
Randomised Controlled Trial
◽
Metastatic Colorectal Cancer
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
The Lancet
◽
10.1016/s0140-6736(19)30723-8
◽
2019
◽
Vol 393
(10189)
◽
pp. 2404-2415
◽
Cited By ~ 233
Author(s):
Brian I Rini
◽
Thomas Powles
◽
Michael B Atkins
◽
Bernard Escudier
◽
David F McDermott
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Randomised Controlled Trial
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States
The Journal of Urology
◽
10.1016/j.juro.2016.05.113
◽
2016
◽
Vol 196
(4)
◽
pp. 1096-1104
◽
Cited By ~ 31
Author(s):
Samir S. Taneja
◽
James Bennett
◽
Jonathan Coleman
◽
Robert Grubb
◽
Gerald Andriole
◽
...
Keyword(s):
Prostate Cancer
◽
United States
◽
Photodynamic Therapy
◽
Phase I
◽
The United States
◽
Multicenter Trial
◽
Low Risk
◽
Risk Prostate Cancer
◽
Low Risk Prostate Cancer
◽
Targeted Photodynamic Therapy
Download Full-text
Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate-to-severe anaemia in India: a multicentre, open-label, phase 3, randomised, controlled trial
The Lancet Global Health
◽
10.1016/s2214-109x(19)30427-9
◽
2019
◽
Vol 7
(12)
◽
pp. e1706-e1716
◽
Cited By ~ 6
Author(s):
Sutapa B Neogi
◽
Niveditha Devasenapathy
◽
Ranjana Singh
◽
Himanshu Bhushan
◽
Duru Shah
◽
...
Keyword(s):
Randomised Controlled Trial
◽
Pregnant Women
◽
Controlled Trial
◽
Intravenous Iron
◽
Severe Anaemia
◽
Iron Sucrose
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Faculty Opinions recommendation of Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.717950273.793455532
◽
2012
◽
Author(s):
Alexander Eggermont
Keyword(s):
Randomised Controlled Trial
◽
Metastatic Melanoma
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer
The Lancet Oncology
◽
10.1016/s1470-2045(17)30170-5
◽
2017
◽
Vol 18
(4)
◽
pp. e187
◽
Cited By ~ 2
Author(s):
Weigang Yan
◽
Yi Zhou
◽
Zhien Zhou
◽
Zhigang Ji
◽
Hanzhong Li
Keyword(s):
Prostate Cancer
◽
Photodynamic Therapy
◽
Active Surveillance
◽
Low Risk
◽
Risk Prostate Cancer
◽
Low Risk Prostate Cancer
◽
Targeted Photodynamic Therapy
Download Full-text
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
The Lancet Oncology
◽
10.1016/s1470-2045(20)30452-6
◽
2020
◽
Vol 21
(10)
◽
pp. 1317-1330
◽
Cited By ~ 3
Author(s):
Shaji K Kumar
◽
Susanna J Jacobus
◽
Adam D Cohen
◽
Matthias Weiss
◽
Natalie Callander
◽
...
Keyword(s):
Multiple Myeloma
◽
Stem Cell
◽
Randomised Controlled Trial
◽
Stem Cell Transplantation
◽
Controlled Trial
◽
Newly Diagnosed
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer – Authors' reply
The Lancet Oncology
◽
10.1016/s1470-2045(17)30163-8
◽
2017
◽
Vol 18
(4)
◽
pp. e188
◽
Cited By ~ 3
Author(s):
Abdel-Rahmène Azzouzi
◽
Mark Emberton
Keyword(s):
Prostate Cancer
◽
Photodynamic Therapy
◽
Active Surveillance
◽
Low Risk
◽
Risk Prostate Cancer
◽
Low Risk Prostate Cancer
◽
Targeted Photodynamic Therapy
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close